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N1. Introduction
The development of new drugs is currently a long and costly process
in large part due to the failure of promising drug candidates identiﬁed in
initial in vitro screens to perform as intended in vivo. New approaches
to drug screening are being developed which focus on providing more
biomimetic platforms. This review surveys this new generation of
drug screening technologies, and provides an overview of recent52
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discovery through stem cell-bdevelopments in organoid culture systemswhich could afford previous-
ly unmatched ﬁdelity for testing bioactivity and toxicity. The challenges
inherent in such approaches will also be discussed, with a view towards
bridging the gap between proof-of-concept studies and a wider imple-
mentation within the drug development community.
Drug discovery today is at a crossroads: while increasingly large and
varied compound libraries are synthesized and tested in primary
screens, the promise of the identiﬁed lead compounds remains largely
unrealized. Indeed, while tremendous investments in automation
have enabled the costs and turnaround time for large to medium-scale
primary screening to fall signiﬁcantly [1], the gap between lead com-
pound validation and success in the clinic is still wide, suggesting that
a process still beset by signiﬁcant limitations in efﬁciency.ased organoidmodels, Adv. DrugDeliv. Rev. (2014), http://dx.doi.org/
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2 A. Ranga et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxxTo a signiﬁcant degree, this inefﬁciency in taking lead compounds
into the clinic may be due to the discrepancy between the simpliﬁed
in vitro assays currently performed and the complexity of real in vivo pa-
thologies. Indeed, while both drug safety and efﬁcacy intrinsically linked
to administration into a complex and heterogeneous three-dimensional
(3D) physiological system, most primary drug screening campaigns are
still carried out with cell lines grown on two-dimensional (2D) plastic,
an entirely reductionist approach where important parts of the drug-
biology interaction are lost. The outcome of this primary screening pro-
cess is the identiﬁcation of “hits”, which satisfy very speciﬁc molecular
targets or phenotypic requirements. A key problem is that these lead
compounds are then validated and optimized in similarly over-
simpliﬁed culture models. The process of ADMET evaluation (adsorp-
tion, distribution, metabolism, excretion, toxicology), while having
undergone signiﬁcant improvements in the last 15 years [2], could
still be considered one of themain bottlenecks in the drug development
process and could afford the greatest return on technological innova-
tions [3].
As an important additional requirement, regulatory agencies require
that identiﬁed pro-drugs be tested in two animal models before
granting approval to proceed to any human clinical trials. This costly
process of validation in animal models often fails due to physiological
events linked to fundamental differences between human and animal
model physiology. At this increasingly costly step, due to well-known
differences in mechanisms of metabolism and toxicology between spe-
cies, there remains a signiﬁcant lack of ﬁdelity between current testing
procedures and human outcomes, particularly as related to appropriate
evaluation of toxicity and drug dose.
These shortcomings have been clearly recognized within the phar-
maceutical industry [4], yet few fundamental solutions have currently
been implemented. The behavior of cells and their response to drugs
continue to be studied in vitromostly in 2D cell cultures that completely
fail to mimic the complexity of themicroenvironment. Not surprisingly,
drug responsiveness in these settings is therefore often not predictive ofU
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Fig. 1. 3D assays could bridge the gap between primary screening and animal and human trials
low cost to few compounds in high-cost high-risk trials. The process of lead optimization and
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the in vivo situation, which dramatically increases the costs of drug
discovery.
At the same time, a vast amount of research has been carried out in
academia to develop more relevant test-beds for screening and valida-
tion efforts (Fig. 1). In particular, there has been a push towards the
development of multicellular spheroid models [5], notably in cancer
modeling [6], aswell as a number ofminiaturized approaches culminat-
ing in organ-on-chip systems [7]. More recently, there has been a tre-
mendous interest in developing increasingly complex multicellular
constructs termed “organoids” [8–10] (Fig. 2). These morphogenetic
models, often recapitulating developmental programs from embryology
or harnessing adult stem cell-based regenerative processes, have
allowed molecular and cell biologists to understand key signaling
events required for the initiation and maintenance of multicellular
organs. By recapitulating not only the form but also the rudiments of
function of their in vivo counterparts, these constructs have the poten-
tial to move from laboratory proof-of-concepts to relevant tools in the
drug discovery pipeline. Indeed, such organoids could ﬁnally provide a
key missing link between compound screening and clinical trials, and
could serve as models for testing drug efﬁcacy in target organs, for
toxicity in liver models or for bioavailability through intestinal system
models. In particular, by using primary human cells, especially
patient-derived cells with relevant pathologies in conjunction with
cellular reprogramming strategies, these techniques could provide an
invaluable link to disease-speciﬁc human drug screening models.
Ultimately, the wider implementation of these bio-mimicking ap-
proaches within a still-conservative drug development community
will require the level of reproducibility and consistency currently
achieved with cell lines. Thus, such culture models will require 3D cul-
ture conditions which afford the needed ﬂexibility to achieve precise
control over the cellularmicroenvironment aswell as a level of scalabil-
ity. Furthermore, the applicability of such models will be greatly en-
hanced by adapting to existing infrastructure, notably automatic
robotic platforms for experimental setup and assay readouts.. Drug discovery pipeline typically proceeds frommultiple compounds tested at relatively
validation can beneﬁt from increasingly representative in vitro technologies.
ased organoidmodels, Adv. DrugDeliv. Rev. (2014), http://dx.doi.org/
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Fig. 2. Current organoidmodels. (A) An ever-increasing number of organs have in vitro organoid equivalents. Organoid-based assays present a novel and potentially high-value de-risking
strategy, particularly when generated as iPS cell-derived disease models. (B) Among recently reported self-assembling cellular constructs, cerebral [73], intestinal [43] and hepatic [44]
organoids are prominent examples of organoid cultures with potential applications in drug discovery.
Reproduced by permission of Nature Publishing Group.
3A. Ranga et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxxThus the purpose of this review isﬁrst to provide a selected survey of
existing state-of-the-art 3D models of in vitro drug evaluation, then to
introduce some key recent developments in organoid systems, and ﬁ-
nally, through a critical evaluation of the limitations of such systems,
to propose some advances which could lead to the adoption of such
models by making the case for a real functional value in helping de-
risk this process. T 167168
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C2. From phenotype to organotype: high-throughput screening andthe 3D paradigm
2.1. Phenotypic screens: an additional dimension
Phenotypic drug discovery has become increasingly popular in early
stage drug discovery. Unlike target-based screens, in phenotypic screens,
there is no a priori understanding of themolecular mechanism of action,
and the effect of compounds on cell phenotype is observed directly. Such
an approach has emphasized the importance of biologically-focused as-
says: between 1999 and 2008, in a period where target-based screens
still predominated the drug discovery process, out of 75 ﬁrst-in-class
drugs with new molecular mechanism of action approved by the US
Food andDrug Administration, the contribution of phenotypic screening
to the discovery of ﬁrst-in-class small-molecule drugs exceeded that of
target-based approaches — with 28 and 17 of these drugs coming from
the two approaches, respectively [11]. As cell-based assays continue
to gain prominence and widespread adoption, it is clear that the new
approaches focused on further enhancing biological relevance are
necessary.
In the last few years, there has been a signiﬁcant effort to develop 3D
culture systemswhich better represent in vivo biology. Within this vast
ﬁeld, there have also been numerous approaches focused on high-
throughput and miniaturized implementations of such technologies.
Here,wewill present such approaches, particularly focusing onmost re-
cent developments pertaining to implementation in high-throughput
systems. Oncology has been one of the most important targets of drug
discovery; in this ﬁeld where the presentation of the pathology is
often heterogeneous, and drug effectiveness, resistance and toxicity
manifest itself in many ways. It is therefore in this ﬁeld that a number
of advances in the creation of more physiologically relevant approaches
have been most prominent. Indeed, using a number of established cellPlease cite this article as: A. Ranga, et al., Drug discovery through stem cell-b
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D
 Plines, the cancer spheroid model as well as complementary assays forinvasion, migration, and angiogenesis have beenmost readily explored.
2.2. Scaffold-free multicellular cancer tumor spheroids
Multicellular cancer tumor spheroids (MCTS) represent a well-
established in vitro model for avascular tumor growth and this model
has become a classic reference for 3D studies [5,12]. By forming an aggre-
gate of cells which form cell–cell interactions, striking changes in mor-
phology and gene expression are evidenced [13] (Fig. 3A) as a number
of pathophysiological characteristics of an in vivo tumor are recreated,
notably, oxygen gradients, glucose distribution, lactate accumulation,
DNA strand breaks, ATP distribution and histomorphology/proliferation
characteristics [14]. It is also particularly appropriate as numerous cancer
cell lines, particularly those from the NCI-60 DTP human tumor cell line
screen established by the NIH, have been shown to form spheroidswith-
out the addition of exogenous matrix materials [14].
For screening purposes, spheroid-forming assays have been devel-
oped in a most rigorously standardized manner within liquid media
cultures. A key consideration in such studies has been the control over
spheroid size, with the intention to establish a spheroid-based screen
with clear pathophysiological gradients but without central necroses
at the onset of treatment [15]. Indeed, a spheroid size of 400 μm was
found to be ideal to recreate hypoxic conditions at the core, as well as
proliferative gradients, which have signiﬁcant impact on radio and
drug-resistance as well as indirect effects of hypoxia-driven gene ex-
pression. Monitoring of spheroid growth kinetics to determine growth
delay and regrowth upon drug administration consists of the primary
analytical endpoint, and is performed by standard phase-contrast imag-
ing. The acid phosphatase assay (APH) has also been established to
monitor cell integrity and viability, with IC50 values estimated from
dose–response curves determined through such an APH cell viability
assessment.
Such a basic approach has been enhancedwith the use of speciﬁcally
designed high-density plates which have been engineered to allow for
high-throughput hanging drop culture systems. Indeed such systems
have been optimized for droplet stability [16], have been shown to be
robust in ﬂuorescence- and colorimetric-based assays through Z-factor
calculations [17], and have allowed for the determination of differential
effects on growth arrest with drugs. For example, ﬂuoracil (5-FU) was
determined to be more effective as an anti-proliferative agent in 2D,ased organoidmodels, Adv. DrugDeliv. Rev. (2014), http://dx.doi.org/
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Fig. 3. State-of-the-art 3D assays allow for evaluation of multicellular tumor spheroid proliferation and quantiﬁcation of angiogenesis and lymphangiogenesis sprouting. (A) Cancer cell
line morphology and proliferation are clearly different between conventional 2D plastic culture and within synthetic PEG hydrogel (actin ﬁlaments stained with rhodamine phalloidin,
nuclei with DAPI) [13]. Reproduced by permission of Elsevier. (B) Isosurface rendering of characteristic VE-cadherin immunoﬂuorescence staining for VE-cadherin from ex vivo 3D
(3D) assay of sprouting angiogenesiswith arterial explants from human umbilical cords inMatrigel™ [74]. Reproduced by permission of American Society of Heamatology. (C) Lymphatic
endothelial cell-coated beads showed cellular protrusions that sprouted into the collagen gel [30]. Effect of lymphangiogenesis inhibitors was quantiﬁed using identiﬁcation of sprout
number per bead by in-house developed software. Reproduced by permission of National Academy of Sciences of the United States of America.
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Owhereas hypoxia activated drugs such as tirapazamine (TPZ) were seen
to bemore effective in 3Dhanging drop cultures [18]. Hanging drop cul-
ture systems have also been recently used in an elegant high-
throughput manner to show how co-culture models of cancer and stro-
mal cells could unveil novel regulatory pathways [19].
2.3. Scaffold-based multicellular cancer tumor spheroids
The generation of large-scale liquid media spheroids has been the
focus of technological advances in up-scaling; by creating “dropletmicro-
arrays”with the possibility of generating thousands of droplets with de-
ﬁned geometry and volume using superhydrophilic–superhydrophobic
patterned surfaces [20], or enhancements in hanging drop spheroid
manipulation through incorporation of magnetic-based technologies
[21].
While these techniques utilizing hanging drop or liquid suspension
cultures provide an undeniable ease of use, such a free-growing con-
struct certainly does not recapitulate the physical constrains experi-
enced by in vitro tumors and may miss important mechanisms of
extracellular interaction-mediated drug resistance. In order to addressPlease cite this article as: A. Ranga, et al., Drug discovery through stem cell-b
10.1016/j.addr.2014.02.006this issue, multiple platforms have been developed to allow cancer
spheroids to be grown within simpliﬁed extracellular matrices (ECM).
To cite only a few recent examples, methylcellulose has been used as a
simple 3D culture system for pancreatic ductal carcinoma cells and
compared to standard 2D culture conditions; in the 3D case cell metab-
olism was seen to shift towards glycolysis, and, notably, while most
drugs tested were shown to be less effective in 3D, two were identiﬁed
as having particularly signiﬁcant effects in this model [22]. In another
study a 3D soft agar matrix was adapted to high-throughput screening,
and 1528 natural product compounds were screened against colorectal
carcinoma colonies [23]. Notably, this study showed how by comparing
tumor-only cells with a co-culture model incorporating colon epithelial
cells, it was possible to distinguish tumor-speciﬁc agents from general
cytotoxic ones. A number of these technologies are now commercially
available and have been shown to be compatible with a number of
downstream assays beyond imaging. For example, in alginate-based
scaffolds while cytotoxicity was measured by AlamarBlue® assay and
drug effectiveness was measured by imaging, additional readouts such
as apoptosis were evaluated by immunohistochemistry and RT-PCR,
where cellular uptake of drugs and nanoparticles could also beased organoidmodels, Adv. DrugDeliv. Rev. (2014), http://dx.doi.org/
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evaluated [24]. Again, it was shown that IC50 values for a number of
cancer drugswere signiﬁcantly higher in a spheroidmodel as compared
to 2D. Thus, as demonstrated in these selected examples, the multi-
cellular tumor spheroid model, despite its simplicity as a ﬁrst approxi-
mation of a 3D tumor microenvironment, has already shown value in
a high-throughput drug discovery pipeline.
2.4. Migration, invasion and angiogenesis in 3D
While aberrant cellular proliferation may be the primary manifesta-
tion of solid tumor cancers, it is via remodeling and migration through
the tissuemicroenvironment thatmalignant cells metastasize to spread
to adjacent tissues or distant sites via lymphatic or angiogenic means. A
better understanding of the role of the microenvironment in initiating
and promoting these processes is critical if the prevention of metastasis
is to be used as a target for oncologic therapeutics. With appropriate 3D
culture models, it is possible to monitor not only bulk volume increases
of spheroids (i.e. tumor proliferation), but also, given appropriatematrix
conditions and chemotactic cues, the outgrowth of individual cells from
such spheroids (i.e. cell migration). A number of approaches to assay
migration and invasion exist, with varying degrees of physiological rel-
evance and ease of implementation [25]. A prominent example includes
ﬁlter-based transwell assays, which can be additionally coated with a
layer of ECM components such as collagen or Matrigel™. More complex
models incorporate a level of dimensionality, such as “sandwich assays”
where a monolayer of cells is entrapped between two layers of ECM.
Most relevantly, cellular spheroids such as the ones described above
can be seeded onto a relevant matrix, or completely embedded within
a 3D matrix [25]. Angiogenesis is one of the central hallmarks of cancer
progression, and signiﬁcant efforts have been carried out to determine
ways to understand and inhibit this process in increasingly biorelevant
model systems [26–28] (Fig. 3B). For example, a 3D vascular network
assay showed considerable sensitivity to several angiogenic inhibitors,
including kinase inhibitors and monoclonal antibodies and led the
development of a 3Dmodel of tumor-driven angiogenesis, in which an-
giogenic outgrowth was sustained by spheroids of prostate cancer cells
in the absence of exogenous growth factors [29]. Another notable use of
3D-based spheroid assays was developed to screen for inhibitors of
lymphangiogenesis [30], a process akin to angiogenesis and highly im-
plicated in tumor progression (Fig. 3C). In this study, spheroids were
formed by coating lymphatic endothelial cells around cytodextran
microcarrier beads, and were then tested in a 3D high-throughput
sprouting assay over the LOPAC collection of pharmacological com-
pounds. By enhancing the power of such a screen by deploying auto-
mated microscopy in conjunction with custom-developed advanced
image processing software, novel regulators of lymphangiogenesis
could be detected. In particular, a previously unknown link was
established between statins and the inhibition of lymphangiogenesis,
which has potential implications not only directly in the treatment of
cancer but also for interactionswith andmanagement of cardiovascular
disease.
2.5. 3D assays for toxicity evaluation
While cancer is a primary target for the deployment of advanced
high-throughput screening strategies, and has been seen in examples
above to beneﬁt from a 3D approach, it is by no means the only area
where spheroid-based assays have been used. Indeed the spheroid
assay has found signiﬁcant use in organ- and cell-type-speciﬁc toxicol-
ogy studies, constituting another important step in the drug validation
process. While dose response and toxicity must clearly be evaluated in
the cell type of interest, systemic toxicity, and particularly liver toxicity,
is also of primary concern. As such, toxicity studies are routinely
performed in HepG2 cells, a hepatocarcinoma cell line which has been
frequently used as a model system to study liver metabolism and cyto-
toxicity. 3D spheroids of HepG2 and closely related HepaRG™ cells havePlease cite this article as: A. Ranga, et al., Drug discovery through stem cell-b
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been cultured in hanging drop suspension cultures and compared to 2D
cultures. In one study, it has been shown that activity of CYP4A4, a
member of the P-450 monooxygenases involved in the metabolism of
a broad range of compounds from steroids to drugs and toxins, was
higher in the 3D cultures compared to 2D [31]. Moreover, 3D cell
cultures weremore sensitive to a drug that is only toxic uponmetabolic
activation in the liver (aﬂatoxin B), suggesting that such an organotypic
system better represents in vivo liver metabolism. Notably, within such
an organotypic culture, the EC50 of acetaminophen was similar to
in vivo toxicity, a phenomenon which could not be reproduced in 2D,
demonstrating once again the importance of a 3D model for capturing
in vivo response [32]. In a further advance, liver microtissues have
also recently been constructed from primary human hepatocytes and
liver-derived non-parenchymal cells [33]. Interestingly, signiﬁcant
species-speciﬁc differences in drug hepatotoxic response were found
between rat and human microtissues [34], highlighting the importance
of developing human cell-based 3D culture systems.
3. Organoids as in vitro organ models: promise and challenges
Despite the increasingly acknowledged value of in vitro 3D culture,
of which some examples were reviewed in the previous section, animal
models have remained as the immediate next test bed for promising
new compounds after an initial primary 2D screen. However there is
a signiﬁcant gap between the still highly simpliﬁed models of spher-
oids and the systemic effects seen in an animal, with all the possible
confounding effects which cannot be clearly deconvolved. Moreover,
there have also been some signiﬁcant data over the years indicating
substantial differences between animal and human modes of drug
response. For example, in a survey of a dozen pharmaceutical com-
panies, with data from 150 compounds with 221 human toxicity
events, data from rodents failed to predict 57% of incidents of
human toxicity [35]. Furthermore, a recent study showed a complete
lack of correlation in the genomic response to acute inﬂammatory
stress between human subjects and murine models, suggesting that
the use of such unrepresentative models may have accounted, thus
far, for the failure of all compounds which have been put through
clinical trials intended to block the inﬂammatory response in criti-
cally ill patients [36].
An ideal in vitro analysis systemwould therefore comprise of human
cells, in a construct complex enough to demonstrate physiologic-like
composition,morphology and heterogeneity and, ideally, the rudiments
of functionality, yet simple enough that it could still be readily assayed
in vitro. Such a construct, capturing some of the complexity of a
human organ in a dish, has been termed “organoid” [37] (Fig. 2). The
idea of creating in vitro organoids is not a newphenomenon: leveraging
cells' intrinsic ability to self-assemble into organized structures has been
envisaged at least since the early generation of teratocarcinomas in
1954 [38]. Indeed, when embryonal carcinoma cells were transplanted
into a host mouse, malignant tumors were found to develop and could
form tissues of all germ layers, and surprisingly, could even in rare
cases develop into complete organs. This became even more relevant
with the advent of embryonic stem cells (ESC), which, under the same
condition, i.e. reimplantation into a host animal, could generate equally
histologically and morphologically complex structures. These early
studies clearly demonstrated the potential of stem cells grown in vitro
to recreate complex and organized structures, albeit when placed in
the context of a complex host microenvironment. As well, these studies
early on demonstrated the need for extrinsicmicroenvironmental regu-
lation for growth and development. In the context of more relevant
physiological studies in vitro, clearly there was an interest and a need
to understand how such processes could be regulated, in order to then
attempt to recreate these processes in vitro.
While the ﬁeld of tissue engineering hasmade signiﬁcant attempts to
recreate in vitro organs in the last 30 years, these approaches have gen-
erally focused on scaffold-based cell seeding techniques, and arguablyased organoidmodels, Adv. DrugDeliv. Rev. (2014), http://dx.doi.org/
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cellular organization found in vivo. More recently, new approaches
based on developmental biology have focused on recreating morpho-
genesis underpinned by a more sophisticated molecular understanding,
with the intent of harnessing the differentiation potential intrinsic in
stem cells to allow for self-organization. Given the right cues, a numberU
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Fig. 4.Organoid culture systems require Matrigel as a 3Dmatrix for structural support and inst
cell and architecture of amini-gut organoid expressing histone 2B-GFP, with ﬁve crypts budding
The American Association for the Advancement of Science and Elsevier. (B) Schematic of cereb
suspension in neural induction medium to form symmetric neuroectoderm, followed by expa
[73]. Reproduced by permission of Nature Publishing Group. (C) Morphogenesis of pancreatic o
by seeding in growth factor-depleted Matrigel™ [53]. Branched organoid after 7 days contain
Please cite this article as: A. Ranga, et al., Drug discovery through stem cell-b
10.1016/j.addr.2014.02.006of increasingly complex structures have been recreated in vitro
(Fig. 2A), which for the ﬁrst time may allow for “function-in-a-dish”.
While their potential uses as replacement organs in regenerative medi-
cine is the clearest and ultimate objective, a more likely and tractable
shorter-term goal is to make use of such constructs in the context of
drug discovery.E
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ructive signaling. (A) Development of an intestinal organoid from a single sorted Lgr5-GFP
from a large central body containing themain lumen [8,75]. Reproduced by permission of
ral organoid multi-step culture system including aggregation of ESCs in embryoid bodies,
nsion of neuroepithelium in Matrigel™ and ﬁnal tissue maturation in spinning bioreactor
rganoids frommouse pancreatic buds composedmainly of bipotent pancreas progenitors
~10,000 cells. Reproduced by permission of The Company of Biologists Limited.
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While spheroid-based approaches may be sufﬁcient for testing drug
efﬁcacy in ablating tumor growth,mitigatingmigration andmodeling to
some extent angiogenesis, such approaches donot allow the equally im-
portant assessment of cytotoxic effects of drugs on a multitude of or-
gans, nor the investigation of issues such as bioavailability when
crossing the intestinal lining, liver metabolism, or blood–brain barrier
effects. As key examples, we will focus here on recent developments
in creating brain, liver and intestinal organoids (Fig. 2B), which could
help in assessing these whole-organ effects.
4. State-of-the-art organoid culture systems: Matrigel™ as
critical component
4.1. Intestinal organoids
In recent years, the organoid system that has gained themost atten-
tion is the mini-gut construct, or intestinal organoid (Fig. 4A). In land-
mark studies by the Clevers group [39–41], it was ﬁrst shown that the
transmembrane protein Lgr5 marks stem cells in the intestinal crypt,
and that such cells exclusively contribute to the rapid self-renewal of
the intestinal epithelium. Based on this in vivo knowledge, experiments
were then carried out to demonstrate how an epithelial cell fragment
isolated from themouse intestinal crypt, when placed in an appropriate
ex-vivo 3D culture system, could generate a 3D construct with some of
the key characteristics of the intestine, including the establishment of a
crypt-villi architecture as well as a lumenized interior [42]. Clearly, the
stem cell niche concept plays a signiﬁcant role in this system: factors
such as R-Spondin, EGF, and Noggin are essential for the maintenance
of the organoids in culture, and Matrigel™, the matrix used as 3D sup-
port, provides a set of structural and biochemical cues. Notably, it has
been found that even a single Lgr5 cell could be sufﬁcient to regrow
an entire organoid, but this process occurred at very low efﬁciency
(circa 5%) [42]. Signiﬁcantly, it has been shown that organoid-forming
efﬁciency was greatly enhanced when Paneth cell-Lgr5 cell doublets
were used, instead of single Lgr5 cells, suggesting that factors secreted
by the Paneth support cell are crucial for regulating the intestinal
niche [43]. Such intestinal organoids have also been derived from
human ES cells [44], thereby greatly enhancing the applicability of
such a system. In turn, it is now possible to envisage that such intestinal
organoids could begin to be used to detect drug–intestine interactions,
and, more speciﬁcally, to investigate bioavailability and aspects of
drug pharmacokinetics. Indeed, intestinal organoids could certainly be
imagined as complement or alternative to the commonly used Caco-2
monolayer transwell assay, which is now the norm as an in vitro
model of human small intestinal mucosa's ability to absorb orally
administered drugs [45].
4.2. Cerebral organoids
The developing human brain acquires its complexity through amyr-
iad of developmental steps, with various cell types and regions acquir-
ing their fate in a tightly regulated and sequential manner. In vitro, it
has been possible to establish 2D cell culture protocols to generate
bulk populations of neuronal subtypes fromESCs for screeningpurposes
in procedures which have become fairly standardized and even in some
cases deployed in primary drug screening assays [46]. With the adop-
tion of 3D culture techniques, it has been possible in recent years to gen-
erate increasingly complex neural subsystems which, to some extent,
preserve their highly restricted in vivo spatial arrangement. Indeed,
the formation of an optic cup from ESCs, including amultilayered neural
retina containing rods and cones,was shown to occur using amulti-step
protocol involving the creation of aggregates in a ﬂoating culture in
serum-free and growth-factor-reduced medium, named SFEBq culture,
or serum-free culture of embryoid body-like aggregates with quick ag-
gregation [47]. The extraordinary self-organization seen in the optic
cup construct involves nonetheless, both in mouse and human systemsPlease cite this article as: A. Ranga, et al., Drug discovery through stem cell-b
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[48], the embedding of aggregates inMatrigel™. Indeed,while itmay be
claimed that the process is entirely driven by spontaneous self-
organization orchestrated by local cellular interactions, it is quite possi-
ble that there are instructivematrix-derived cues at critical points in the
process, which may perhaps even be the initiating impetus for key
symmetry-breaking events within the homogeneous aggregates. More
recently, a similar SFEBq-based protocol has been utilized to develop a
human ESC-derived 3D organoid, termed cerebral organoids, where ex-
tensive patterning of brain regions can be seen, including characteristic
cerebral cortex zones with mature cortical neuron subtypes [49]
(Fig. 4B). In an elegant demonstration of how such an approach could
be used for disease modeling, such a cerebral organoid was modeled
from induced pluripotent stem (iPS) cells derived from a patient pre-
senting with microcephaly, a disorder which has yet to be suitably
reproduced in a mouse model. Such organoids were less developed
than their normal counterparts, with an analysis of the constructs re-
vealing a potential mechanism for disease progression rooted in defec-
tive, premature neuronal differentiation. Proof-of-principle studies
such as this one conﬁrm the promise that patient-derived iPS cells can
serve to better understand disease and to identify potential molecular
targets from a function perspective. In particular, cerebral organoids
could also be further developed to study the blood–brain barrier and
help overcome the difﬁculties in delivering pharmacological agents
into speciﬁc areas of the brain. Such an approach, which would require
at least some measure of vascularization, could potentially be achieved
within a co-culture system, and could potentially identify novel molec-
ular paths to entry or speciﬁc regions of the brainmore sensitive to drug
delivery.E
D
4.3. Liver organoids
Indeed, such a co-culture system has been employed in an approach
focused on generating a liver organoid. A liver bud exhibiting similar
markers to its in vivo counterpart was generated after aggregation of
three cell types at very high cell densities (human umbilical vein endo-
thelial cells (HUVEC), human mesenchymal stem cells (MSC) and iPS
cell-derived hepatic cells) and embedding in Matrigel™ [50]. As in the
neural and intestinal systems, self-organization occurred within the
organoids; here a notable advance involved the additional development
of nascent endothelial networks, which, helped by MSCs thought to
function as a source of pericytes promoting vessel stability [51], allowed
the limb bud to integrate into the host vasculaturewhen implanted into
ectopic extrahepatic sites in a mouse. Within two months in vivo
these organoids matured and resembled adult liver histologically, and
had developed bile canaliculi (though not bile ducts). Importantly,
multiple transplanted liver organoids were able to rescue mice
from subacute gangyclovir-induced liver failure. As with other
newly developed in vitro organoid systems, a fully mature miniatur-
ized organwith a complete set of functional features has not yet been
achieved, but it can be speculated that a better understanding of
complex signaling pathways involved in establishing morphogene-
sis, co-culture approaches and longer maturation times could lead
to the types of function seen here in this case after in vivo implanta-
tion. Still, even immature human-cell based organoids such as the
one depicted here, may be more responsive and predictive of acute
liver injury which is difﬁcult to detect in the course of the current
drug discovery pipeline.
The strikingly complex organoidmodel systems described here rep-
resent only a selection from the rapidly expanding organoid literature.
Indeed, there have also been in the last year reports of such diverse
organoids as the pituitary gland [52], inner ear [49], pancreas [53,54]
(Fig. 4C) and hair follicle [55]. For all these systems, whether derived
from single cells or from pre-aggregated pluripotent stem cells, the
overarching feature has been a signiﬁcant level of self-organization
over time mediated by a 3D matrix.ased organoidmodels, Adv. DrugDeliv. Rev. (2014), http://dx.doi.org/
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Fig. 5.Modular 3D scaffolds enable multifactorial experimentation [68]. Different ligand-
bearing peptides were synthesized (A) and co-assembled into ﬁbrillar hydrogels
(B). HUVECswere cultured in combination of gelswith different combinations of peptides
(C). Full factorial experiments and response surface methodology were used to explore
the direct and interactive effects of various immobilized ligands on cell growth, and opti-
mum formulations that maximized proliferation were identiﬁed (D).
Reproduced by permission of RSC Publishing.
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5. ECMs and3D screening: towards synthetics and scalable approaches
5.1. Engineering better hydrogel systems
A number of challenges present themselves in the pursuit of an
effective translation of these organoid culture systems from an academ-
ic laboratory proof-of-concept to the kind of robust and reliable assay
required for a drug discovery program. The ﬁrst of these challenges is
the need for a reproducible, well-deﬁned and scalable 3Dgel system. In-
deed, all the organoid cultures presented in the previous section made
use of the commercially availableMatrigel™ system,which is an extract
from Engelbreth–Holm–Swarm (EHS) mouse sarcoma, a tumor rich in
ECM proteins. Its main component is Laminin-1, an abundant extracel-
lular component found in basement membrane, while other compo-
nents of Matrigel™ include a mixture of collagen IV (30%) and
entactin (6%) as well as heparin sulfate proteoglycans and a variety of
growth factors in varying proportions, including transforming growth
factor beta (TGFβ), epidermal growth factor (EGF), ﬁbroblast growth
factor (FGF), tissue plasminogen activator, aswell as residualmatrixme-
talloproteinases (MMPs) and growth factors occurring naturally from in
the tumor [56]. It appears clear that the organogenic bioactivity of this
matrix therefore derives both not only from its three-dimensionality
but also from the complex mixture of signaling cues. Yet, Matrigel™ re-
mains a natural extract with relatively imprecise composition and un-
quantiﬁable batch-to-batch variability, rendering it unsuitable for
reproducible and large-scale assays. Furthermore, Matrigel™ presents
a number of practical limitations in handling and processing: it re-
quires careful manipulation and must be maintained at constant
cold temperature throughout cell-encapsulation processes, which
is incompatible with current implementations of large-scale
robotics, which have generally been adapted to handle cell culture
reagents within a different temperature range. Matrigel™ also
tends to have a widely variable degradation proﬁle, which, depend-
ing on handling procedures as well as cell-mediated responses, can
partially degrade in an uncontrolled manner within the time span
of the assay.
Thus, to begin to consider the implementation of organoids as suit-
able in vitro drug discovery tools, a better-deﬁned matrix which
would minimize or preferably completely eliminate animal-derived
components as well as be easy to handle and reproducibly degraded is
necessary. While other puriﬁed natural materials such as alginate and
collagen I have also been shown to support cell encapsulation, it is
doubtful whether such materials could allow for the complex morpho-
genesis seen in Matrigel™, due to their relatively poor abilities to be
functionalized with additional required signaling cues and lack of inde-
pendent modulation of structural and chemical properties.
Currently, synthetic and highly tuneable approaches tomaterials en-
gineering can provide hydrogels with the versatility and consistency
which would be required for large-scale compound screening
(reviewed in [12,57]). Such artiﬁcial ECMs can allow the experimenter
to determine in an independent and highly reproducible manner both
the physical and biochemical properties of such matrices. For example,
poly(ethylene glycol) (PEG)-based hydrogel approaches allow us to
create biophysically active materials. These materials allow for mod-
ulation of mechanical properties as well as cell-mediated degrada-
tion in response to matrix metalloprotease (MMP) secretion [13,
58,59]. For example, in a model of epithelial ovarian cancer, it was
shown by exploiting the design ﬂexibility of the hydrogel character-
istics, that proliferation in 3D was dependent on cell-integrin en-
gagement and on the ability of cells to proteolytically remodel their
immediate extracellular microenvironment while maintain hydrogel
stability in long-term culture [13]. Additionally, it is possible to
chemically tether instructive ECM-derived signals directly onto the
PEG backbone, thereby modulating the biochemical microenviron-
ment. Indeed, by engineering protein or peptide constructs compat-
ible with the chosen cross-linking system [60–62], it is possible toPlease cite this article as: A. Ranga, et al., Drug discovery through stem cell-b
10.1016/j.addr.2014.02.006build a material toolbox whose elements can potentially be used in
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5.2. High-throughput approaches for microenvironment optimization
While Matrigel™ presents multiple and potentially interacting cues,
deﬁned synthetic matrices would need to be precisely tuned to achieve
the required optimal properties. In such a reductionist and deﬁned ap-
proach, the faithful recreation of organoid microenvironments would
have to go beyond the “one-size-ﬁts-all” approach. A Matrigel™-like
organ-speciﬁc synthetic analog would certainly require an as yet un-
known combination of biophysical properties and biochemical signaling
cues, and itwould benecessary to establish a screening paradigm to sys-
tematically identify unique microenvironments which would optimally
support robust and reproducible organoid development.
A number of approaches have been proposed to begin to assess the
effect of large-scale combinatorial biomaterial libraries on cell behavior.
The repurposing of DNAmicroarray printers to producewhat have been
termed “cellular microarrays” has been a particularly popular tech-
nique. In one implementation, a combination of synthetic polymers
with different material properties including wettability, surface topog-
raphy, surface chemistry and elastic modulus were arrayed onto glass
slides and were assessed for their ability to maintain human ESC self-
renewal [64]. In another example, ECM proteins and soluble factors
were assessed in combination to determine optimal conditions for pri-
mary hepatocyte maintenance and early hepatic differentiation of
ESCs [65]. These platforms focused on directly functionalizing micro-
scope slides have relied on cell adhesion to provide a cellular readout.
Other approaches have focused on the creation of structured microwell
arrays which served to entrap cells and could for example track individ-
ual cell fate in a more precise manner via time-lapse microscopy, and
platforms where the simultaneous physical and biochemical properties
of the matrix (i.e. hydrogel substrate stiffness and surface proteinased organoidmodels, Adv. DrugDeliv. Rev. (2014), http://dx.doi.org/
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functionalization) that could bemodulated have enabled trulymultifac-
torial explorations of extrinsic microenvironmental control [66].
5.3. Challenges in implementing engineered organoids
While much can be learned from the combinatorial technologies
seen above, a major limitation has remained that only adherent cells
or cellular aggregates such as neurospheres [67] in liquid media could
be assayed in such systems. Despite technical difﬁculties which have
hampered the use of high-throughput combinatorial studies in 3D, the
deployment of rational approaches based on design of experiment
(DOE) methodologies has proved to be instructive in ways to assess a
combinatorial space for 3D cellular response. In one notable example,
multiple peptide ligands were incorporated into engineered self-
assembling peptide hydrogels. An iterative process consisting of
single-factor experiments for setting initial bounds followed by factorial
experiments for identifying main effects and interactions between li-
gands served to identify previously unknown antagonistic interaction
between the laminin-derived peptide mediating HUVEC cell attach-
ment and growth. In a ﬁnal step, response surface methodology exper-
iments were carried out to identify optimal formulations of these
ligands, which led to endothelial cell growth equivalent to that on na-
tive full-length ﬁbronectin [68] (Fig. 5).
Ultimately, once such synthetic matrices would be deﬁned for an
organoid of interest, it is possible that such artiﬁcial extracellularmicro-
environments could bewidely deployed, either in standardized formats
using liquid handling robots, or viaminiaturized arrays such as the ones
described for toxicity testing [69].With organoidmorphology and func-
tion being signiﬁcantlymore complex than spheroids or single cells, one
important challenge will be in the systematic assessment of function.
More advanced readouts would have to be developed to address these
issues; while confocal microscopy currently provides the standard im-
aging tool for assessing cellular functionwithin such constructs, it is cer-
tainly limited in throughput. As such, newer techniques currently being
developed forwhole animal imaging allowing for rapid and highly accu-
rate scanning of large areas, such as light sheet ﬂuorescencemicroscopy
or high-resolution optical coherence tomography could be deployed in
this context. Light-sheet microscopy, where only the ﬂuorophores in
the light sheet's plane contribute to the image, is particularly useful in
reducing out-of-focus blur from three-dimensional samples [70]. Addi-
tionally, a technique known as biodynamic imaging, which uses short-
coherence dynamic light scattering to evaluate intracellular motions
[71], has recently been speciﬁcally applied to study the multicellular
cancer spheroidmodel. However, the key for such promising new imag-
ing technologies to gain wider applicationwill be to modify them in ap-
propriate ways in order to conform to the standardized formats and
throughput required in the drug discovery process. Furthermore,
image analysis tools focused on simple cellular morphologies would
have to be adapted and customized to yield relevant and quantitative
data. Beyond imaging, a number of multiplexed techniques could also
be used to interrogate for functional outputs and to maximize sample
value. For example, Luminex/XMAP bead-based assays can be used to
detect hundreds of proteins or genes of interest within a single sample,
while gene expression can be assessed by such technologies as the
Fluidigm qPCR gene expression proﬁling system [72] as well with as a
battery of increasingly inexpensive sequencing technologies. Today,
some pharmaceutical companies are actively.
6. Conclusions and outlook
Numerous studies have now shown the advantages of 3D cell culture,
in particular in the context of the multi-cellular tumor spheroid model,
with notably different drug responses compared to 2D contexts which
in some cases compare favorably to the in vivo observations. Such 3D
cultures have also been used to demonstrate more physiological re-
sponses in other contexts such as migration, invasion, angiogenesis andPlease cite this article as: A. Ranga, et al., Drug discovery through stem cell-b
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lymphangiogenesis, as well as in toxicology. We have proposed in this
review that complex self-organized organoids, which have recently
come to the fore as striking proof-of-concept examples of in vitro devel-
opmental biology, could be appropriate test platforms for future drug
discovery efforts. Indeed, such miniaturized proto-organs could be used
as a signiﬁcant validation bridge between primary high-throughput
screening and costly animal and human trials. Safety and efﬁcacy of
lead compounds could be tested directly on in vitro organs for the target
pathology. It could also be imagined that in the context of oncology, cells
and tumor response could be assessed not only in isolation but in amore
realistic co-culture system within an organ of interest. Ultimately, such
organoid systems could be systemically linked in order to begin to
build a “human in a dish” as a technology with unprecedented ﬁdelity
to human disease and drug response. Today, the promise of such trans-
formative advances is largely limited by issues of historical importance
in the drug discovery process: reproducibility, standardization, valida-
tion and quality control. For these far-reaching objectives to be accom-
plished and for such technologies to move from the university
laboratory to a broader use in the commercial drug discovery process,
we have emphasized the need to focus on implementations based on
synthetic and tailored 3D matrices amenable to medium to large-scale
automation, as well as meaningful multiplexed readouts.
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